VRDN at a glance
Viridian Therapeutics, Inc.\DE (VRDN, SEC CIK 1590750) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as August 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Viridian Therapeutics, Inc.\DE (VRDN) reported revenue of $70.8 million (up 23359.9% from FY2024) and a net loss of $342.6 million.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Viridian Therapeutics, Inc.\DE (VRDN) shares worth $987.5 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Tousignant Jennifer on August 19, 2026 of 10,000 shares at $24.50 per share.
- In the last 90 days, VRDN insiders reported 0 open-market purchases ($0) and 2 open-market sales ($348K) on Form 4, a net sale of $348K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $70.8M
- +23359.9% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$348K
- 13F holders
- 27 funds
- $987.5M · −3 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core biopharma focus on autoimmune and rare diseases, emphasizing best-in-class therapies for thyroid eye disease (TED) and related conditions
- New subcutaneous IGF-1R antibody elegrobart in pivotal phase 3 (REVEAL-1/2) for TED with potential auto-injector, complementing intravenous veligrotug
- Strategic shift to commercial launch prep for veligrotug post-BLA acceptance (Priority Review, PDUFA June 30, 2026) and building U.S. commercial infrastructure
- Over 300 patients enrolled in safety databases for veligrotug and elegrobart exceeding targets; phase 3 TED trial enrollment higher than anticipated (>330 total)
- Introduction of TSHR inhibitor program targeting Graves’ disease and TED, with IND planned for Q4 2026, expanding pipeline beyond IGF-1R and FcRn inhibitors
Risk Factors
- Regulatory risk: FDA may require additional patients or steps for veligrotug and elegrobart phase 3 trials, risking approval delays or denials
- Geopolitical exposure: Clinical trial operations in Israel and China vulnerable to adverse regulatory actions or unrest impacting progress
- Operational vulnerability: Dependence on third-party CDMOs and CROs for manufacturing and trial conduct risks delays or non-compliance (cGMP, cGCP)
- Competitive risk: Delays or failures in clinical trials could allow competitors to market similar therapies earlier, impairing commercial prospects
- Financial risk: Net loss $342.6M in 2025, cash $874.7M enabling operations ~12 months; inability to raise capital may force program scale-backs or bankruptcy
Management Discussion & Analysis
- Revenue $70.8M in 2025 vs $0.3M in 2024; increase driven by $70M upfront license payment from Kissei and related party collaborations
- Research & Development expenses $338.9M in 2025 vs $238.3M in 2024; TED portfolio R&D up $78.3M, driven by phase 3 trials and milestone fees
- Selling, General & Administrative expenses $95.3M in 2025 vs $61.1M in 2024; increased by $34.2M to support commercial infrastructure buildout
- Net loss $342.6M in 2025 vs $269.9M in 2024; loss widened by $72.7M reflecting increased R&D and SG&A spend
AI summary of the VRDN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly added debt-service risk triggered by May 2026 issuance of $250.0 million 1.75% convertible senior notes due 2032
- Most materially updated liquidity risk: $981.5 million cash, cash equivalents, and marketable securities expected to fund operations at least twelve months
- DRI milestone-financing risk: up to $130.0 million remains available but depends on elegrobart trials, regulatory approvals, or commercial sales
- Elegrobart regulatory risk: failed autoinjector bioequivalence could significantly delay or abandon its BLA and marketing approval
- Clinical-development risk: FDA or other authorities may require more than the planned 300-patient elegrobart safety database
AI summary of the VRDN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 text contains only exhibit liability and incorporation disclaimers
- No fiscal-year 2026 operating results or financial figures disclosed in the provided excerpt
Item EX-99.1: Item EX-99.1
- Lumvoa FDA-approved June 26 and launched immediately, transitioning Viridian into commercial operations with early physician and payer traction
- Sales team engaged 95% of 2,000 core prescribing physicians; first doses administered in July, supporting initial demand but not yet revenue scale
Item 7.01: Regulation FD Disclosure
- Regulation FD disclosure furnished, not filed under Exchange Act Section 18
- Disclosure excluded from automatic incorporation into other SEC filings
Item 8.01: Other Events
- FDA approval of Lumvoa (veligrotug-vvze) for TED regardless of activity or duration
- First TED treatment labeled with data covering both active and chronic disease
Item EX-99.1: Item EX-99.1
- FDA approval makes Lumvoa Viridian’s first commercial product, enabling immediate U.S. launch for TED regardless of disease activity or duration
- Label covers both active and chronic TED, expanding the addressable treatment population versus activity-limited therapies
Item 5.07: Submission of Matters to a Vote of Security Holders
- All two Class II nominees elected through 2029, with Jennifer Moses receiving 86,378,842 votes for
- KPMG ratified as independent auditor for fiscal 2026, with 92,866,008 votes for
AI summaries of VRDN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VRDN
Don't miss the next VRDN filing
- Alerts as it files. A push when VRDN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VRDN, by share count.
- Ask anything. An AI agent that reads every VRDN filing and answers with sources.
VRDN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Tousignant Jennifer | M | Aug 19, 2026 | 10,000 | $14.41 |
| Tousignant Jennifer | Sell | Aug 19, 2026 | 10,000 | $24.50 |
| Tousignant Jennifer | M | Aug 19, 2026 | 10,000 | - |
| Tousignant Jennifer | Sell | Aug 19, 2026 | 4,212 | $24.50 |
| Tripuraneni Radhika | M | Aug 14, 2026 | 40,000 | - |
| Tripuraneni Radhika | M | Aug 14, 2026 | 40,000 | $13.21 |
| CAIN CHRISTOPHER W. | A | Jul 1, 2026 | 32,341 | - |
| Ajer Jeffrey Robert | A | Jul 1, 2026 | 32,341 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $302K | $70.8M |
| Operating Income | -$254.4M | -$299.0M | -$363.4M |
| Net Income | -$237.7M | -$269.9M | -$342.6M |
| Op. Margin | - | -99018.2% | -512.9% |
| Net Margin | - | -89387.1% | -483.6% |
| Balance Sheet | |||
| Total Assets | $490.4M | $742.4M | $899.4M |
| Equity | $442.0M | $671.6M | $722.2M |
| ROE | -53.8% | -40.2% | -47.4% |
| Per Share | |||
| EPS | $-5.31 | - | - |
| Cash Flow | |||
| Operating CF | - | -$232.3M | -$276.4M |
| CapEx | $898K | $511K | $495K |
Source: XBRL data in Viridian Therapeutics, Inc.\DE (VRDN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate VRDN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $987.5M |
| Q1 2026 | 30 | $933.1M |
| Q4 2025 | 24 | $1.33B |
| Q3 2025 | 24 | $676.5M |
| Q2 2025 | 24 | $452.7M |
| Q1 2025 | 22 | $330.3M |
| Q4 2024 | 19 | $456.9M |
| Q3 2024 | 14 | $123.0M |
- T. Rowe Price Group+2.54M (+79%)
- State Street Corp+1.45M (+31%)
- FMR LLC (Fidelity)+1.23M (+8%)
- Vanguard Portfolio Management LLC+1.11M (+68%)
- Dimensional Fund Advisors+1.08M (+204%)
- Citadel Advisors LLC−2.28M (-98%)
- JPMorgan Chase & Co−419.9K (-40%)
- Bank of America Corp−219.3K (-19%)
- Morgan Stanley−141.3K (-16%)
- D.E. Shaw & Co−80.3K (-6%)
- Allstate+15.0K
- Raymond James Financial−293.3K
- Millennium Management−140.6K
- Principal Financial Group−75.2K
- Two Sigma Investments−35.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VRDN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 20, 2026 | - | - | |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| SC 13G | Jun 26, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 8-K | May 28, 2026 | - | Analysis | |
| 8-K | May 26, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| SC 13G | May 8, 2026 | - | - | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
VRDN SEC filings: frequently asked questions
Are VRDN insiders buying or selling?
In the last 90 days, Viridian Therapeutics, Inc.\DE (VRDN) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $348,194 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold VRDN stock?
As of June 30, 2026, the largest Viridian Therapeutics, Inc.\DE (VRDN) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($305.0 million), BlackRock ($157.1 million), State Street Corp ($112.5 million), T. Rowe Price Group ($105.6 million), Vanguard Capital Management LLC ($84.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VRDN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Viridian Therapeutics, Inc.\DE (VRDN) reported revenue of $70.8 million (up 23359.9% from FY2024) and a net loss of $342.6 million. The figures come from the XBRL data in the 10-K.
What are the main risks in VRDN's latest 10-K?
In the 10-K filed February 26, 2026, Viridian Therapeutics, Inc.\DE (VRDN) flagged: Regulatory risk: FDA may require additional patients or steps for veligrotug and elegrobart phase 3 trials, risking approval delays or denials. Geopolitical exposure: Clinical trial operations in Israel and China vulnerable to adverse regulatory actions or unrest impacting progress. (AI summary of the Risk Factors section.)
What did VRDN report in its latest 8-K?
Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 text contains only exhibit liability and incorporation disclaimers.
What are the latest VRDN SEC filings?
Viridian Therapeutics, Inc.\DE (VRDN) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on August 20, 2026.
What is VRDN's SEC CIK number?
Viridian Therapeutics, Inc.\DE (VRDN)'s SEC Central Index Key (CIK) is 1590750. EDGAR lists every VRDN filing under that number.
Ask anything about VRDN
The research agent reads VRDN's filings, financials, insider trades and 13F holders, then answers with sources.